Publications by authors named "Akshayee Kale"
Introduction: Gestational exposure to valproate has been associated with a wide range of adverse pregnancy outcomes, including major congenital malformations in offspring. However, to date, no meta-analysis has comprehensively examined the risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children gestationally exposed to valproate.
Methods: We searched MEDLINE, Embase, and Scopus from inception until 15 May 2024 for relevant English-language articles.
Article Synopsis
- The study explored the acceptability and feasibility of telemedicine-assisted buprenorphine induction (TABI) for treating opioid use disorder in India.
- Among the 60 patients enrolled, a high retention rate of 88.3% during the TABI program and 83.3% at the 3-month follow-up was observed.
- Patient satisfaction was moderate, with 58.3% satisfied, but only 25% would recommend TABI, indicating the need for additional research to enhance its effectiveness and wider implementation.
Article Synopsis
- There is a potential link between immune function and cognition in schizophrenia, but this study aimed to explore the same relationship in patients with Acute and Transient Psychotic Disorders (ATPDs), an illness similar to schizophrenia.
- Researchers analyzed a group of 19 ATPD patients during their acute phase and again after remission, comparing their cognitive performance using the Montreal Cognitive Assessment Scale (MoCA) to individuals with schizophrenia in remission.
- Results showed that ATPD patients had notable cognitive deficits during both phases of their illness, but no significant connection was found between immune marker levels (IL-6, IL-8, IL-17) and cognitive scores in either group.
Aim: Considering Acute and Transient psychotic disorders (ATPDs) to be a close entity to Schizophrenia (SZ) with a completely different course and outcome, studies evaluating the immunological abnormalities are scarce in ATPDs. We analysed immune-mediated inflammatory marker levels [Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-17 (IL-17) and Tumour necrosis factor-alpha (TNF-α)] in patients with ATPDs (in the acute phase and after remission), and compared these with patients with SZ in remission and with healthy controls.
Methods: Ninteen subjects with ATPDs in acute phase of illness were age-/gender-matched with healthy controls and patients with schizophrenia in remission; recruited through purposive sampling.